Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161084125> ?p ?o ?g. }
- W2161084125 endingPage "854" @default.
- W2161084125 startingPage "849" @default.
- W2161084125 abstract "The prognosis of patients with peripheral T-cell lymphoma (PTCL) treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) is poor, but their laboratory prognostic parameters had not previously been evaluated. We retrospectively reviewed 55 patients with newly diagnosed PTCL treated with CHOP from August 1999 to May 2009 at our institution. We analyzed six laboratory parameters, including thymidine kinase (TK) activity, to evaluate overall survival, which was the primary end-point. In multivariate analysis, the overall survival was significantly worse in patients with high TK activity (hazard ratio 34.8, 95% confidence interval [CI] 1.03–1176.23). The overall response rate among patients with high TK activity was 21.4%, significantly poorer compared with other parameters (p = 0.001). High TK activity predicts poor overall survival among patients with newly diagnosed PTCL treated with CHOP. Response to CHOP treatment is significantly decreased in patients with PTCL with high TK activity." @default.
- W2161084125 created "2016-06-24" @default.
- W2161084125 creator A5010120453 @default.
- W2161084125 creator A5018910129 @default.
- W2161084125 creator A5025950763 @default.
- W2161084125 creator A5031782171 @default.
- W2161084125 creator A5038191750 @default.
- W2161084125 creator A5041607240 @default.
- W2161084125 creator A5047640708 @default.
- W2161084125 creator A5049198126 @default.
- W2161084125 creator A5050980051 @default.
- W2161084125 creator A5061465699 @default.
- W2161084125 creator A5064541531 @default.
- W2161084125 creator A5075163335 @default.
- W2161084125 date "2011-10-31" @default.
- W2161084125 modified "2023-09-25" @default.
- W2161084125 title "High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone" @default.
- W2161084125 cites W1512843295 @default.
- W2161084125 cites W1599354919 @default.
- W2161084125 cites W1962291688 @default.
- W2161084125 cites W1969178587 @default.
- W2161084125 cites W1981535645 @default.
- W2161084125 cites W1991696977 @default.
- W2161084125 cites W1995287920 @default.
- W2161084125 cites W1999637438 @default.
- W2161084125 cites W2011333667 @default.
- W2161084125 cites W2022864747 @default.
- W2161084125 cites W2044390815 @default.
- W2161084125 cites W2044656530 @default.
- W2161084125 cites W2047385586 @default.
- W2161084125 cites W2055235688 @default.
- W2161084125 cites W2060320162 @default.
- W2161084125 cites W2062882719 @default.
- W2161084125 cites W2094388623 @default.
- W2161084125 cites W2095905668 @default.
- W2161084125 cites W2097519758 @default.
- W2161084125 cites W2099059207 @default.
- W2161084125 cites W2105425540 @default.
- W2161084125 cites W2123807140 @default.
- W2161084125 cites W2126486896 @default.
- W2161084125 cites W2133267160 @default.
- W2161084125 cites W2134210438 @default.
- W2161084125 cites W2140865464 @default.
- W2161084125 cites W2145638148 @default.
- W2161084125 cites W2154927166 @default.
- W2161084125 cites W2161548168 @default.
- W2161084125 cites W2162693374 @default.
- W2161084125 cites W2200858253 @default.
- W2161084125 cites W2315161045 @default.
- W2161084125 cites W2416844197 @default.
- W2161084125 cites W332844036 @default.
- W2161084125 cites W37889860 @default.
- W2161084125 cites W4205736005 @default.
- W2161084125 cites W4243182105 @default.
- W2161084125 doi "https://doi.org/10.3109/10428194.2011.635858" @default.
- W2161084125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22035416" @default.
- W2161084125 hasPublicationYear "2011" @default.
- W2161084125 type Work @default.
- W2161084125 sameAs 2161084125 @default.
- W2161084125 citedByCount "2" @default.
- W2161084125 countsByYear W21610841252013 @default.
- W2161084125 crossrefType "journal-article" @default.
- W2161084125 hasAuthorship W2161084125A5010120453 @default.
- W2161084125 hasAuthorship W2161084125A5018910129 @default.
- W2161084125 hasAuthorship W2161084125A5025950763 @default.
- W2161084125 hasAuthorship W2161084125A5031782171 @default.
- W2161084125 hasAuthorship W2161084125A5038191750 @default.
- W2161084125 hasAuthorship W2161084125A5041607240 @default.
- W2161084125 hasAuthorship W2161084125A5047640708 @default.
- W2161084125 hasAuthorship W2161084125A5049198126 @default.
- W2161084125 hasAuthorship W2161084125A5050980051 @default.
- W2161084125 hasAuthorship W2161084125A5061465699 @default.
- W2161084125 hasAuthorship W2161084125A5064541531 @default.
- W2161084125 hasAuthorship W2161084125A5075163335 @default.
- W2161084125 hasConcept C126322002 @default.
- W2161084125 hasConcept C143998085 @default.
- W2161084125 hasConcept C203014093 @default.
- W2161084125 hasConcept C207103383 @default.
- W2161084125 hasConcept C2776090121 @default.
- W2161084125 hasConcept C2776694085 @default.
- W2161084125 hasConcept C2776755627 @default.
- W2161084125 hasConcept C2777891184 @default.
- W2161084125 hasConcept C2778720950 @default.
- W2161084125 hasConcept C2779338263 @default.
- W2161084125 hasConcept C2779429289 @default.
- W2161084125 hasConcept C2779725641 @default.
- W2161084125 hasConcept C44249647 @default.
- W2161084125 hasConcept C71924100 @default.
- W2161084125 hasConcept C8891405 @default.
- W2161084125 hasConcept C90924648 @default.
- W2161084125 hasConceptScore W2161084125C126322002 @default.
- W2161084125 hasConceptScore W2161084125C143998085 @default.
- W2161084125 hasConceptScore W2161084125C203014093 @default.
- W2161084125 hasConceptScore W2161084125C207103383 @default.
- W2161084125 hasConceptScore W2161084125C2776090121 @default.
- W2161084125 hasConceptScore W2161084125C2776694085 @default.
- W2161084125 hasConceptScore W2161084125C2776755627 @default.
- W2161084125 hasConceptScore W2161084125C2777891184 @default.